Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 33

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
.4%)
    9 (6.5%)
    20 (9.7%)
  
    Musculoskeletal and connective tissue disorders

    Arthralgia
    4 (6.0%)
    16 (11.5%)
    20 (9.7%)
  
    Nervous system disorders

    Headache
    7 (10.4%)
    14 (10.1%)
    21 (10.2%)

24

The Company believes these
findings from the Phase 2 results indicate that XPro may offer benefits to a readily identified subgroup of Alzheimer’s patients
across all ages with biomarker-defined neuroinflammation, regardless of comorbidities or ApoE4 status and potentially lays the foundation
for advancing XPro as a promising treatment for AD. The Company is planning an end-of-phase 2 meeting with the FDA, which is expected
to occur towards the end of 2025, to determine next steps and expects to be eligible for Break Through status.

25

CORDStrom,
developed by INmune Bio circa 2020, represents a breakthrough in mesenchymal stromal cell technology. The CORDStrom platform leverages,
among other things, proprietary screening, pooling and expansion techniques to create off-the-shelf, allogeneic, pooled human umbilical
cord -derived mesenchymal stromal cells (HucMSCs) as medicines to treat complex inflammatory diseases. CORDStrom products are designed
to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured, potent cellular medicines that can be
produced at low cost and with repeatable specification. Initially developed at the INKmune manufacturing facilities utilizing United Kingdom
academic grant funding, CORDStrom is a product platform that shows promise as a therapy for RDEB and many other debilitating conditions.
While the first generation CORDStrom product is agnostic to indication, the platform enables creation of indication-specific products,
which can be tuned for optimization of anti-inflammatory, immunomodulatory, wound healing, and other characteristics.

The
CORDStrom product platform shares many similarities, including raw materials, equipment, and procedures, with the Company’s INKmune
oncology product, enabling the Company to leverage economies of scale, experienced staff, and other resources to strategically manufacture
both products in a rotational campaign